AXTA vs CC
Axalta vs The Chemours Company — AI-powered side-by-side comparison
VS
CC
The Chemours Company
44
Reduce
| Metric | AXTA | CC |
|---|
| AI Score |
66
|
44
|
| Price |
$37.27
|
$14.81
|
| P/E Ratio |
22.87×
|
-7.40×
|
| ROE |
16.1%
|
-154.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
32.6%
|
15.3%
|
| Debt / Equity |
1.22×
|
-82.92×
|
| Dividend Yield |
0.0%
|
2.4%
|
| RSI (14) |
65.4
|
36.7
|
| Beta |
1.239
|
1.428
|
| Expected Upside |
+0.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for AXTA versus CC.
AXTA leads by 22 points.
AXTA scores 66/100 (Buy) versus CC at 44/100 (Reduce).
AXTA Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 26.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 26.9% signals elevated volatility — Risk
CC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -1.4% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.37 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 7.1x prices in significant intangible value — Value
- ROE of only -164.4% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 16.56 adds balance-sheet risk to the value case — Value